229 related articles for article (PubMed ID: 12010169)
1. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.
Levin AS
Clin Microbiol Infect; 2002 Mar; 8(3):144-53. PubMed ID: 12010169
[TBL] [Abstract][Full Text] [Related]
2. Use of inhaled ampicillin-sulbactam against multiresistant Acinetobacter baumannii in bronchial secretions of intensive care unit patients.
Horianopoulou M; Kanellopoulou M; Paraskevopoulos I; Kyriakidis A; Legakis NJ; Lambropoulos S
Clin Microbiol Infect; 2004 Jan; 10(1):85-6. PubMed ID: 14706094
[No Abstract] [Full Text] [Related]
3. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii.
Corbella X; Ariza J; Ardanuy C; Vuelta M; Tubau F; Sora M; Pujol M; Gudiol F
J Antimicrob Chemother; 1998 Dec; 42(6):793-802. PubMed ID: 10052904
[TBL] [Abstract][Full Text] [Related]
4. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus.
Urban C; Go E; Mariano N; Berger BJ; Avraham I; Rubin D; Rahal JJ
J Infect Dis; 1993 Feb; 167(2):448-51. PubMed ID: 8421178
[TBL] [Abstract][Full Text] [Related]
5. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
Sayin Kutlu S; Saçar S; Süzer T; Cevahir N; Okke D; Dirgen Caylak S; Turgut H
Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
[TBL] [Abstract][Full Text] [Related]
6. Ampicillin/sulbactam: current status in severe bacterial infections.
Rafailidis PI; Ioannidou EN; Falagas ME
Drugs; 2007; 67(13):1829-49. PubMed ID: 17722953
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter bacteremia.
Choi JY; Kim CO; Park YS; Yoon HJ; Shin SY; Kim YK; Kim MS; Kim YA; Song YG; Yong D; Lee K; Kim JM
Yonsei Med J; 2006 Feb; 47(1):63-9. PubMed ID: 16502486
[TBL] [Abstract][Full Text] [Related]
8. Extensively-drug resistant
Gkentzi D; Tsintoni A; Christopoulou I; Mamalis I; Paliogianni F; Assimakopoulos SF; Marangos M; Dimitriou G
J Chemother; 2020 Apr; 32(2):103-106. PubMed ID: 31992156
[No Abstract] [Full Text] [Related]
9. Sulbactam-containing beta-lactamase inhibitor combinations.
Akova M
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
[TBL] [Abstract][Full Text] [Related]
10. [Assessment of efficacies of imipenem, cefoperazone-sulbactam and cefepime in rats with experimental thigh abscess model with multidrug resistant and susceptible Acinetobacter baumannii strains].
Yıldırım MI; Tuğrul HM
Mikrobiyol Bul; 2011 Jul; 45(3):422-9. PubMed ID: 21935775
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
[TBL] [Abstract][Full Text] [Related]
12. [Is sulbactam really the answer for treatment of infections caused by multiresistant strains of Acinetobacter spp.?].
Casellas JM; Dana R
Enferm Infecc Microbiol Clin; 1997; 15(6):335-6. PubMed ID: 9376409
[No Abstract] [Full Text] [Related]
13. In vitro activity of eravacycline and cefoperazone/ sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece.
Meletis G; Protonotariou E; Gkeka I; Kassomenaki A; Mantzana P; Tychala A; Vlachodimou N; Kourti A; Skoura L
New Microbiol; 2022 Jul; 45(3):210-212. PubMed ID: 35920876
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Zhao C; Xie W; Zhang W; Ye Z; Wu H
Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
Lai HH; Liou BH; Chang YY; Kuo SC; Lee YT; Chen TL; Fung CP
J Microbiol Immunol Infect; 2016 Jun; 49(3):371-7. PubMed ID: 25081987
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
Liu B; Bai Y; Liu Y; Di X; Zhang X; Wang R; Wang J
J Chemother; 2015 Oct; 27(5):271-6. PubMed ID: 25068186
[TBL] [Abstract][Full Text] [Related]
18. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
[TBL] [Abstract][Full Text] [Related]
19. Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Lin HS; Lee MH; Cheng CW; Hsu PC; Leu HS; Huang CT; Ye JJ
Infect Dis (Lond); 2015 Jun; 47(6):370-8. PubMed ID: 25746600
[TBL] [Abstract][Full Text] [Related]
20. Meningitis with multidrug-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.
Kendirli T; Aydín HI; Hacíhamdioğlu D; Gülgün M; Unay B; Akín R; Lenk MK; Gökçay E
J Hosp Infect; 2004 Apr; 56(4):328. PubMed ID: 15066747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
